Education
About Us
Working with TipRanks
Follow Us
Rallybio (RLYB)
NASDAQ:RLYB
RLYB Stock Chart & Stats
$0.78
-$0.04(-3.69%)
At close: 4:00 PM EST
$0.78
-$0.04(-3.69%)
Day’s Range― - ―
52-Week Range$0.22 - $1.08
Previous CloseN/A
Volume36.64K
Average Volume (3M)283.42K
Market Cap
$33.10M
Enterprise Value-$30.53M
Total Cash (Recent Filing)$59.32M
Total Debt (Recent Filing)$198.00K
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 17, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding42,243,774
10 Day Avg. Volume220,035
30 Day Avg. Volume283,421
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)65.73
P/FCF Ratio-0.85
Enterprise Value/Market Cap-0.92
Enterprise Value/Revenue-45.30
Enterprise Value/Gross Profit-47.41
Enterprise Value/Ebitda2.01
Forecast
1Y Price Target
$1.00Price Target Upside28.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StrategyThe recent workforce reduction plan and sale of REV102 interest should provide cash runway into mid-2027.
Pipeline DevelopmentRallybio will now focus its resources on advancing other pipeline programs, notably RLYB116, an inhibitor of complement component 5 (C5) with potential applications in treating complement-related diseases.
Regulatory ApprovalPh2 Study Of '212 In Pregnant Women At Higher Risk For FNAIT received green lights from EU's EMA and UK's MHRA, allowing the start of the trial.
Bears Say
Clinical Trial SetbacksRLYB212 failed to meet the minimum target PK concentration and there is not enough data to accurately dose adjust safely.
EarningsRLYB reported a 2Q25 net loss of $9.7M.
Program DiscontinuationRallybio has announced the discontinuation of its RLYB212 program, which was undergoing development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Rallybio News
RLYB FAQ
What was Rallybio’s price range in the past 12 months?
Rallybio lowest stock price was $0.22 and its highest was $1.08 in the past 12 months.
What is Rallybio’s market cap?
Rallybio’s market cap is $33.10M.
When is Rallybio’s upcoming earnings report date?
Rallybio’s upcoming earnings report date is Mar 17, 2026 which is in 82 days.
How were Rallybio’s earnings last quarter?
Rallybio released its earnings results on Nov 06, 2025. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of -$0.213 by $0.573.
Is Rallybio overvalued?
According to Wall Street analysts Rallybio’s price is currently Undervalued.
Does Rallybio pay dividends?
Rallybio does not currently pay dividends.
What is Rallybio’s EPS estimate?
Rallybio’s EPS estimate is -0.15.
How many shares outstanding does Rallybio have?
Rallybio has 42,243,774 shares outstanding.
What happened to Rallybio’s price movement after its last earnings report?
Rallybio reported an EPS of $0.36 in its last earnings report, beating expectations of -$0.213. Following the earnings report the stock price went up 3.226%.
Which hedge fund is a major shareholder of Rallybio?
Currently, no hedge funds are holding shares in RLYB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rallybio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.00 (28.21% Upside)
$1.00 (28.21% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.80%
12-Months-Change
Fundamentals
Return on Equity
-21.17%
Trailing 12-Months
Asset Growth
-44.82%
Trailing 12-Months
Company Description
Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
RLYB Stock 12 Month Forecast
Average Price Target
$1.00
▲(28.21% Upside)
Technical Analysis
Moleculin Biotech
―
Aptevo Therapeutics
―
Citius Pharmaceuticals
―
Processa Pharmaceuticals
―
Allarity Therapeutics
―
Ownership Overview
14.23%
Insiders
2.74% Mutual Funds
54.72% Other Institutional Investors
26.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---